The total expenditure on central schemes for the poor and on the major subsidies exceeds the states' share of central taxes. These schemes are chronic bad performers due to a culture of immunity in public administration and weakened local governments. Arguing that the poor should be trusted to use these resources better than the state, a radical redirection with substantial direct transfers to individuals and complementary decentralisation to local governments...

-Outlook The government today cleared the National Pharmaceutical Pricing Policy that will bring 348 essential drugs under price control, leading to reduction in prices. "The National Pharmaceutical Pricing policy has been approved by the Cabinet with an objective to put in place a regulatory framework for pricing of drugs to ensure their availability at reasonable prices," an official source said. At present, the government through the National Pharmaceutical Pricing Authority (NPPA) controls prices...

-Tehelka Policy flaw lets private players jack up prices and siphon off massive government subsidies. TO DROUGHTS and abject poverty, farmers can add another crisis: sky-rocketing fertiliser prices. The issue has prompted eight chief ministers of large states to seek the intervention of the Ministry of Chemicals and Fertilisers (MoCF) in the matter. Consider, for example, di-ammonium phosphate (DAP) and muriate of potash (MoP), two fertilisers that used to have massive demand...

-The Telegraph One Singh has told the Congress what another Singh probably wants to: create a political environment conducive for reducing subsidies. Planning Commission deputy chairman Montek Singh Ahluwalia has told Congress MPs that subsidy cuts are essential if India has to preserve its growth momentum — a statement more in line with the known views of Prime Minister Manmohan Singh than the populist line preferred by many Congress leaders. Many Congress MPs,...

-The Economic Times It's not just the drug regulator, where a parliamentary panel has alleged corruption, failing in its job. Drug regulation across entities that dot this broad landscape is in poor health and ineffective. In May, when a Parliamentary panel, during a routine examination of healthcare regulatory bodies, alleged corruption in the approval of new drugs, it was merely pointing out one symptom. Such symptoms pervade the entire drug regulation landscape,...